Human colorectal tumor cell lines were established which express wildtype p21 or p21 with a mutation at codon 46 (Cys) or 140 (Gly) on IPTG treatment (LacSwitch). The IPTG-induced wildtype p21 bound to CDK2 and PCNA and inhibited CDK activity in the cells and reduced cell growth rate; whereas, both IPTG-induced mutated p21 proteins neither bound to CDK2 nor a ected the CDK activity but did bind to PCNA, and they did not a ect the cell growth rate. Wildtype p21 suppressed apoptosis and enhanced survival of X-ray-irradiated or adriamycintreated cells; but, mutated p21 neither suppressed apoptosis nor a ected cell survival. When cells were treated with mimosine, a p53-independent p21-inducer, or butyrolactone I, a speci®c inhibitor of CDK, cellular endogenous p21 was induced and X-ray or adriamycininduced apoptosis was blocked. These results suggest that CDK-binding or CDK-inhibitory activity of p21 is required to prevent apoptosis, i.e., CDK is required for apoptosis in human tumor cells.